NCT07130448Not yet recruiting
The Relation of Albumin/Globulin Ratio and Platelet/Albumin Ratio to Lupus Nephritis
The Relation of Albumin/Globulin Ratio and Platelet/Albumin Ratio to Lupus Nephritis in Upper Egypt ( Single Center Study)
Source: ClinicalTrials.gov · Last updated 19 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Albumin/globulin ratio and platelet/albumin ratio as a predictive non-invasive biomarker for lupus nephritis (LN) presence and severity
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 10 Aug 2025
- Start date
- 1 Sept 2025
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- Assiut University
- Diseases
- Lupus (SLE)
- NCT number
- NCT07130448
What you commit to
- Study type: Observational
- Planned participants: 120
- From 1 Sept 2025 to the primary completion date, 30 Sept 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients on nephrotoxic medications not related to SLE management.
Other illness
- Recent infections or acute inflammatory conditions.
Lab values
- Patients with chronic liver disease, hematological disorders, or malignancies affecting albumin/globulin ratio or platelet counts.
Who the study is looking for
- Patients aged 18 years or older diagnosed as SLE according to 2019 ACR/EULAR classification criteria and with lupus nephritis (LN) according to the ACR criteria.
- Patients with available baseline laboratory investigations and renal biopsy.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.